• +1-646-491-9876
    • +91-20-67278686

    Search

    Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016

    Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016

    • Report Code ID: RW0001499733
    • Category Pharmaceuticals
    • No. of Pages 60
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.

    Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Hypertrophic Cardiomyopathy.

    Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents

    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Hypertrophic Cardiomyopathy Overview 7
    Therapeutics Development 8
    Pipeline Products for Hypertrophic Cardiomyopathy - Overview 8
    Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 9
    Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 10
    Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 11
    Hypertrophic Cardiomyopathy - Pipeline Products Glance 12
    Late Stage Products 12
    Clinical Stage Products 13
    Early Stage Products 14
    Hypertrophic Cardiomyopathy - Products under Development by Companies 15
    Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 16
    Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 17
    Gilead Sciences Inc 17
    Heart Metabolics Ltd 18
    Lead Discovery Center GmbH 19
    miRagen Therapeutics Inc 20
    MyoKardia Inc 21
    Hypertrophic Cardiomyopathy - Therapeutics Assessment 22
    Assessment by Monotherapy Products 22
    Assessment by Target 23
    Assessment by Mechanism of Action 25
    Assessment by Route of Administration 27
    Assessment by Molecule Type 28
    Drug Profiles 30
    eleclazine - Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    HCM-2 - Drug Profile 32
    Product Description 32
    Mechanism Of Action 32
    R&D Progress 32
    LUS-1 - Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    MGN-9103 - Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    MYK-461 - Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    perhexiline maleate - Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    ranolazine ER - Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    Small Molecule for Cardiac Hypertrophy - Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    Hypertrophic Cardiomyopathy - Dormant Projects 46
    Hypertrophic Cardiomyopathy - Discontinued Products 47
    Hypertrophic Cardiomyopathy - Product Development Milestones 48
    Featured News & Press Releases 48
    Nov 11, 2016: MyoKardia Announces Exploratory Digital Health Substudy as Part of PIONEER-HCM Trial of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 48
    Nov 02, 2016: MyoKardia Announces Dosing of First Patient in Phase 2 PIONEER-HCM Study of MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy 48
    Sep 21, 2016: MyoKardia Outlines Path to Registration for MYK-461 in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients and Provides Pipeline and Research Updates at Inaugural R&D Day 49
    Aug 31, 2016: Heart Metabolics Announces Initiation of Phase 2b Study of Perhexiline for Hypertrophic Cardiomyopathy 51
    Jul 14, 2016: SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy 52
    Jul 11, 2016: MyoKardia Announces Topline Clinical Data Supporting Advancement of MYK-461 to Phase 2 PIONEER-HCM Study in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients 53
    May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 54
    Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 55
    Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 55
    Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 56
    Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 57
    Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 58
    Appendix 59
    Methodology 59
    Coverage 59
    Secondary Research 59
    Primary Research 59
    Expert Panel Validation 59
    Contact Us 59
    Disclaimer 60

    List of Tables

    Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
    Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
    Number of Products under Development by Companies, H2 2016 10
    Number of Products under Investigation by Universities/Institutes, H2 2016 11
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Clinical Stage Development, H2 2016 13
    Comparative Analysis by Early Stage Development, H2 2016 14
    Products under Development by Companies, H2 2016 15
    Products under Investigation by Universities/Institutes, H2 2016 16
    Hypertrophic Cardiomyopathy - Pipeline by Gilead Sciences Inc, H2 2016 17
    Hypertrophic Cardiomyopathy - Pipeline by Heart Metabolics Ltd, H2 2016 18
    Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, H2 2016 19
    Hypertrophic Cardiomyopathy - Pipeline by miRagen Therapeutics Inc, H2 2016 20
    Hypertrophic Cardiomyopathy - Pipeline by MyoKardia Inc, H2 2016 21
    Assessment by Monotherapy Products, H2 2016 22
    Number of Products by Stage and Target, H2 2016 24
    Number of Products by Stage and Mechanism of Action, H2 2016 26
    Number of Products by Stage and Route of Administration, H2 2016 27
    Number of Products by Stage and Molecule Type, H2 2016 29
    Hypertrophic Cardiomyopathy - Dormant Projects, H2 2016 46
    Hypertrophic Cardiomyopathy - Discontinued Products, H2 2016 47

    List of Figures

    Number of Products under Development for Hypertrophic Cardiomyopathy, H2 2016 8
    Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H2 2016 9
    Number of Products under Development by Companies, H2 2016 10
    Comparative Analysis by Early Stage Products, H2 2016 14
    Assessment by Monotherapy Products, H2 2016 22
    Number of Products by Targets, H2 2016 23
    Number of Products by Stage and Targets, H2 2016 23
    Number of Products by Mechanism of Actions, H2 2016 25
    Number of Products by Stage and Mechanism of Actions, H2 2016 25
    Number of Products by Stage and Routes of Administration, H2 2016 27
    Number of Products by Molecule Types, H2 2016 28
    Number of Products by Stage and Molecule Types, H2 2016 28
    Gilead Sciences Inc
    Heart Metabolics Ltd
    Lead Discovery Center GmbH
    miRagen Therapeutics Inc
    MyoKardia Inc

    Request for Sample

    Report Url http://www.reportsweb.com//hypertrophic-cardiomyopathy-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//hypertrophic-cardiomyopathy-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//hypertrophic-cardiomyopathy-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments